Saudi Pharmaceutical Industries and Medical Appliances Corporation, commonly known as SPIMACO, is a leading player in the pharmaceutical and medical devices sector, headquartered in Saudi Arabia. Established in 1986, SPIMACO has made significant strides in the industry, focusing on the development, manufacturing, and distribution of high-quality pharmaceutical products and medical appliances across the Middle East and North Africa. The company offers a diverse range of core products, including prescription medications, over-the-counter drugs, and medical devices, distinguished by their commitment to innovation and quality. SPIMACO's strategic position in the market is underscored by its robust manufacturing capabilities and adherence to international standards, making it a trusted name in healthcare. With a strong emphasis on research and development, SPIMACO continues to enhance its product portfolio, contributing to the advancement of healthcare in the region.
How does Saudi Pharmaceutical Industries and Medical Appliances Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Saudi Pharmaceutical Industries and Medical Appliances Corporation's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Saudi Pharmaceutical Industries and Medical Appliances Corporation, headquartered in Saudi Arabia, currently does not have available carbon emissions data for the most recent year. As such, there are no specific figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions. Additionally, the company has not outlined any formal reduction targets or commitments to climate initiatives, such as those set by the Science Based Targets initiative (SBTi). There are no documented climate pledges or reduction initiatives reported. In the absence of specific emissions data and climate commitments, it is important to note that the pharmaceutical industry is increasingly focusing on sustainability and reducing carbon emissions. Companies in this sector are often encouraged to adopt best practices in environmental management and set measurable targets to mitigate their impact on climate change.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Saudi Pharmaceutical Industries and Medical Appliances Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

